Cetuximab biosimilar (Shanghai Zhangjiang Biotechnology)

西妥昔单抗生物类似药（上海张江生物）

Report date: 2026/05/25 20:02:40

Base Information

Drug NameCetuximab biosimilar (Shanghai Zhangjiang Biotechnology)
Drug Alias Namecetuximab beta西妥昔单抗生物仿制药（上海张江生物）Cetuximab biobetter重组抗EGFR人鼠嵌合单抗（上海张江生物）Recombinant anti-EGFR chimeric antibody (Shanghai Zhangjiang Biotechnology) +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsColorectal NeoplasmsNeoplasms
Global Approved IndicationsColorectal Neoplasms
Approved Indications in ChinaColorectal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2024/06/18
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Zhangjiang Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHainan Xiansheng Re Ming Pharmaceutical Co LtdTaizhou Mabtech Pharmaceutical Co Ltd
Inactive CompaniesShanghai Zhangjiang Biotechnology Co Ltd
Active IndicationsColorectal Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeL01XC06
Related LinksN/A